Europe has significant vaccine research and development expertise - the home of 60% of global vaccine research and development. Cooperation between research institutions in Europe is critical to maintain and further develop expertise and competencies as well as to ensure the future of vaccine manufacture, research, and development in Europe. Currently there is little cooperation between R&D groups, assay developers and vaccine producers.

TRANSVAC is changing this by creating a network of European stakeholders involved in vaccine research and development. This network was initially established by thirteen partners but TRANSVAC is based on the principle that any European group may request to join, should they be able to bring relevant experience for mutual benefit. TRANSVAC aims to provide a vaccine development platform that may be accessed by external groups in order to provide expertise and technologies in order to accelerate the development of new vaccines. TRANSVAC’s vaccine development facilities are not linked to any particular disease.